For most of its history, the Indian diagnostics business has spoken a simple language. Patients fell ill, doctors prescribed tests, and laboratories collected, processed and reported results as fast and as cheaply as they could.

The vocabulary was operational: collection centres, turnaround time, sample logistics, network density, cost per test. It was a commodity processing business, and it competed on cost.

Listen to the same companies today, and the vocabulary has changed.

The investor communications from Dr Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostic Centre and the newly listed Suraksha Diagnostic are full of a different set of words: genomics (reading a patient's genes), next-generation sequencing, AI-assisted pathology, liquid biopsy, molecular oncology and pharmacogenomics.

The framing comes from the top. Dr Lal's executive chairman, Arvind Lal, has called the shift a move "from disease detection to disease prediction".

Each of these is a distinct technology with its own economics, and together they describe an industry trying to climb out of the commodity tier into one where capability, not cost, decides the contest. It is worth taking them one at a time.

The New Toolkit

Genomics is the furthest along. Genomics reads the DNA itself, looking for the mutations that cause or predict disease.

Dr Lal has built the deepest pipeline through its Genevolve division, now around five years old, which offers more than 160 genomic tests spanning cancer, inherited disorders, neurological conditions and reproductive health, supported by four reference laboratories and roughly 3,000 prescribing clinicians. Dr Lal is based in the Delhi region.

Metropolis, the Mumbai-headquartered chain, got there by acquisition rather than construction, buying the oncology speciality laboratory Core Diagnostics, where cancer-gene testing already contributes about a quarter of high-end revenue, alongside a library of more than 40,000 stored and catalogued patient samples.

Suraksha, based in Kolkata, launched a dedicated genomics vertical in July 2025, committing Rs 22 crore upfront and a further Rs 46 crore over two years, and Vijaya intends to enter with a new automated laboratory in Hyderabad. Between them, the four cover the country: Dr Lal in the north, Metropolis in the west, Vijaya in the south and Suraksha in the east.

A clinical sequencing menu takes years to validate, which is what makes a head start in it durable in a way a head start in routine pathology never was.

Next-generation sequencing, or NGS, is the platform underneath much of this: machinery that reads hundreds of genes at once rather than testing for one mutation at a time. Dr Lal was the first in India to introduce a 500-gene cancer test, which is only affordable because the machine collapses hundreds of separate checks into a single run; Metropolis runs one of the country's widest such menus.

The significance is that NGS turns each test into a data-generation exercise, producing far more information than the immediate clinical question requires. That surplus is an asset the routine tier never creates.

AI-assisted pathology is where the technology stops being merely the test and becomes part of the interpretation.

Dr Lal uses artificial intelligence to help its pathologists read prostate and breast cancer slides, grading how aggressive a tumour looks and spotting whether it has begun to spread, and says it is the first laboratory in India to use a deep-learning tool that catches cancer in lymph nodes, even the tiny deposits a human eye can miss.

Metropolis runs an engine, MetAdvisor, that tailors a patient's tests to their medical history.

This compounds the surplus data that sequencing creates: more reporting volume trains better models, which attract more specialists, which generate more data.

That flywheel is how technology businesses pull away once they reach scale, and it is the part of the precision tier a discounter cannot price-match, because a thyroid result confers no such advantage on whoever runs it.

Liquid biopsy is the most futuristic modality now in commercial use. Rather than cutting tissue, it reads fragments of DNA that cells shed into the bloodstream, so a blood draw can do the work of a surgical sample.

Dr Lal is the only private laboratory in India to offer the donor-derived version of the test, which spots a transplanted organ being rejected from a blood sample rather than an invasive biopsy; the same science lets a tumour be tracked in the blood through treatment.

It needs not only the sequencing hardware but the software that can pick a real signal out of the genetic noise, which is precisely why it does not yield to discounting.

Molecular oncology ties these threads together, and it carries the commercial weight. Cancer is the domain where sequencing, AI interpretation and liquid biopsy converge, because treatment now depends on the molecular profile of the tumour rather than its location in the body.

Metropolis draws roughly 70% of its cancer-gene revenue from the most advanced tests, and has launched a panel that screens healthy people for inherited cancer risk and a kit that lets women collect their own cervical-cancer sample at home.

Dr Lal expects oncology and genetics to see significant traction, and its chief executive, Shankha Banerjee, calls the company's new premium platform Sovaaka a foray into "AI-powered precision health screening".

This builds loyalty. Once an oncologist comes to trust a lab’s cancer-gene reports, they keep sending patients back, a habit no cheap blood test can create.

Pharmacogenomics sits a little further out but follows the same logic, and both Dr Lal and Suraksha have flagged it. It uses a patient's genes to predict which drugs will work for them and at what dose, turning a one-off test into a reference a clinician consults for years. The routine tier sells a result, and the transaction ends; this sells something that keeps being used.

Why It Pays

All five modalities reshape the economics of the diagnostics business.

Routine pathology has steadily become a commodity.

A standard blood test is largely indistinguishable across laboratories, giving discount chains and online aggregators room to compete primarily on price.

Precision diagnostics operates differently.

These tests carry higher realisations, face limited price competition because credible alternatives remain scarce, and generate additional revenue without requiring laboratories to build an entirely new operating backbone.

For large diagnostic chains, the economics are compelling. Selling another sequencing panel to an existing oncology referral is cheaper and more profitable than acquiring a new customer for a routine blood test. At that point, the value of a nationwide network lies not just in processing more samples, but in extracting more revenue from the same infrastructure.

The genuine technology shift should not be confused with wellness packaging, which often shares the same investor deck. Preventive bundles such as Dr Lal's Swasthfit, now 27% of revenue, or Metropolis's TruHealth, up 21% in FY26, repackage routine tests in a consumer wrapper.

They lift engagement and lifetime value, but a rival can copy a bundle within a quarter; it cannot copy a sequencing platform, the software to interpret it and an oncologist referral base in the same time.

The wellness layer is marketing. The precision tier is the moat.

This is where a large network's spare capacity begins to translate into pricing power rather than mere volume, though how early this is deserves honesty.

Dr Lal does not break out Genevolve's revenue. Metropolis reports a combined high-end segment at around 37% of revenue rather than a clean genomics figure.

No filing includes an India-specific market estimate for genomics; the only number the industry cites, roughly Rs 400 to Rs 500 crore, covers molecular diagnostics as a whole, a broader category still dominated by routine infection tests such as PCR swabs used during the pandemic.

Investors are funding the build-out on strategic logic rather than demonstrated returns, and the missing segment reporting is something analysts should press management to remedy.

What The Market Values

Yet the market has already drawn its conclusion. Vijaya trades at around 78 times earnings, Metropolis at 60x, Dr Lal at 54x, even the discounter Thyrocare at 51x.

Those are not the multiples of a sample-processing business, but a bet that the laboratories with the deepest sequencing, interpretation and molecular capabilities will own the part of diagnostics worth owning.

Metropolis's chairperson, Ameera Shah, frames the prize the same way, arguing the next phase will be defined by genomic intelligence "embedded into clinical workflows at scale".

The next phase, then, will not be won by whoever processes the most samples at the lowest cost. That fight is becoming a low-margin war that discounters and online platforms are built to wage.

It will be won by whoever can sequence, interpret and act on biology in ways a rival cannot reproduce, by the laboratories that have stopped thinking of themselves as processors and started thinking of themselves as technology companies that happen to run on blood and tissue.